跳至主要内容
临床试验/NCT04723979
NCT04723979已完成不适用

Clinical Use and Outcome of NovoSeven® Treatment in Severe Postpartum Haemorrhage - Experiences From an Observational Multi-country (UK, DK, FR, NL) Retrospective Cohort Study

Leiden University Medical Center1 个研究点 分布在 1 个国家目标入组 3,322 人开始时间: 2020年5月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
3,322
试验地点
1
主要终点
Occurrence of invasive procedures (yes/no)

研究概览

简要总结

The overall aim of this project is to include currently available information from women with severe postpartum haemorrhage (sPPH) who were treated with NovoSeven® and to examine whether NovoSeven® may have affected the course of the PPH in these women, specifically the control of bleeding. Data will be included from previous cohort studies from four countries: United Kingdom (UK), the Netherlands, Denmark, and France.

详细描述

This is a retrospective non-interventional cohort study of women with sPPH who were treated with NovoSeven® or other standard of care. The analyses will be done utilising data that were collected for other purposes in four countries. The data include four previously established cohorts from the UK, France, Denmark and The Netherlands. In short, these population-based studies collected data, using enhanced systems, from the medical records of the women who met the case definition for each of the respective studies. Data are available from approximately 1260 (Netherlands, 39 exposed to NovoSeven®), 1655 (France, 18 exposed to NovoSeven®), 245 (DK, 28 exposed to NovoSeven®) and 162 (UK, 13 exposed to NovoSeven®) patients with persistent PPH.

Information regarding patient characteristics, concomitant treatment and outcomes in PPH women treated with NovoSeven® is limited in many countries. The current study will therefore include a description of women with PPH treated with NovoSeven®, or standard of care in each of the four cohorts. This will also include an assessment of the comparability of the cohorts and the overall rate of clinical outcomes in the study population. To aid in this assessment propensity scores will be calculated and used to match the women with an event of sPPH treated with NovoSeven® and those that are not.

The UK and Danish datasets were national and the datasets from Netherlands, and France were from multiple regions. The TeMpOH-1 study in the Netherlands collected data from 75% of national births. The EPIMOMS study in France collected data from six regions: Alsace, Lorraine, Auvergne, Rhone-Alpes, Ile-de-France and Basse-Normandie and these regions represented 18% of national births.

Data come from the below described cohorts.

Denmark: The Danish data were identified and collected using the Danish Medical Birth Registry (DMBR) and the Danish Trans-fusion Database (DTD). During the period 2001-2009, women who had a birth identified in the DMBR and had transfused 10 or more units of red blood cells (RBC) within 24 hours identified from DTD were included in study. The DMBR collects information on all births in Denmark and this includes clinical and demographic data from each birth. The DTD is a national database and contains information of the quantity and type of blood products transfused and the time of each transfusion. Additional data were extracted from the patient charts (Study II in the PhD thesis(PubMed ID 29510809)).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Inclusion in one of the four cohorts (DK, FR, NL, UK)

排除标准

  • there are no exclusion criteria

研究组 & 干预措施

Exposed to recombinant FVIIa (NovoSeven®)

all women exposed to NovoSeven® during sPPH

干预措施: Eptacog alfa (Drug)

Exposed to recombinant FVIIa (NovoSeven®)

all women exposed to NovoSeven® during sPPH

干预措施: Standard of care (Other)

Standard of Care

Women with postpartum hemorrhage not exposed to NovoSeven®.

干预措施: Standard of care (Other)

结局指标

主要结局

Occurrence of invasive procedures (yes/no)

时间窗: 20 minutes - 24 hours following time_zero

Invasive procedures are defined as: uterine or iliac artery ligation, radiological arterial embolisation, uterine compression sutures, or hysterectomy. Time0 is defined as time of first administration of NovoSeven®. It occurs x minutes after onset of sPPH. For matched controls: Time0 is derived from the matching process. It is equal to the period from onset of sPPH to time of first administration of NovoSeven® for the patient for which they are a matched control.

次要结局

  • Amount of blood products transfused(From birth to 24 hours after time_zero)
  • Occurrence of hysterectomy, yes/no(20 minutes - 24 hours following time_zero)
  • Occurrence of thromboembolic events, yes/no(From time_zero until 5 days after time_zero)
  • Estimated blood loss(From birth to 24 hours after time_zero)

研究者

发起方
Leiden University Medical Center
申办方类型
Other
责任方
Principal Investigator
主要研究者

Johanna G. van der Bom

Professor of Clinical Epidemiology

Leiden University Medical Center

研究点 (1)

Loading locations...

相似试验